Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bright Minds Biosciences Inc (DRUG.CN)

Bright Minds Biosciences Inc (DRUG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,365
  • Shares Outstanding, K 4,464
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,372 K
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.22
Trade DRUG.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.77
  • Most Recent Earnings $-0.44 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4700 +12.24%
on 03/26/24
1.6500 unch
on 04/24/24
-0.1500 (-8.33%)
since 03/15/24
3-Month
1.4700 +12.24%
on 03/26/24
3.0700 -46.25%
on 02/02/24
-0.7900 (-32.38%)
since 01/24/24
52-Week
1.4700 +12.24%
on 03/26/24
8.5800 -80.77%
on 08/08/23
-2.2500 (-57.69%)
since 04/21/23

Most Recent Stories

More News
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

/CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company specializing in the...

DRUG.CN : 1.6500 (unch)
DRUG : 1.0900 (-2.68%)
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effects as a near-death experience (NDE). The study...

HCA : 319.02 (-0.13%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)
LFST : 6.17 (+0.98%)
NUMIF : 0.0595 (-0.83%)
NUMI.TO : 0.0800 (-5.88%)
ACHC : 71.19 (+0.64%)
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

/PRNewswire/ -- A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same...

NUMI.TO : 0.0800 (-5.88%)
DRUG.CN : 1.6500 (unch)
NUMIF : 0.0595 (-0.83%)
HCA : 319.02 (-0.13%)
DRUG : 1.0900 (-2.68%)
LFST : 6.17 (+0.98%)
ACHC : 71.19 (+0.64%)
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – October 5, 2022 –  A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking...

HCA : 319.02 (-0.13%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)
LFST : 6.17 (+0.98%)
ACHC : 71.19 (+0.64%)
NUMI.TO : 0.0800 (-5.88%)
NUMIF : 0.0595 (-0.83%)
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.340 (+4.62%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.340 (+4.62%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May ...

OTC.VN : 0.340 (+4.62%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of...

DRUG.CN : 1.6500 (unch)
DRUG : 1.0900 (-2.68%)
OTC.VN : 0.340 (+4.62%)
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British...

OTC.VN : 0.340 (+4.62%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE:...

OTC.VN : 0.340 (+4.62%)
DRUG : 1.0900 (-2.68%)
DRUG.CN : 1.6500 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders...

See More

Key Turning Points

3rd Resistance Point 1.6500
2nd Resistance Point 1.6500
1st Resistance Point 1.6500
Last Price 1.6500
1st Support Level 1.6500
2nd Support Level 1.6500
3rd Support Level 1.6500

See More

52-Week High 8.5800
Fibonacci 61.8% 5.8640
Fibonacci 50% 5.0250
Fibonacci 38.2% 4.1860
Last Price 1.6500
52-Week Low 1.4700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar